article thumbnail

AstraZeneca Pauses Vaccine Trial for Safety Review

NY Times

The company halted late-stage trials of its coronavirus vaccine because of a serious suspected adverse reaction in a participant.

article thumbnail

Allergic reactions prompt Moderna COVID vaccine pause in California

pharmaphorum

Public health authorities in California are seeking a halt on dosing of one lot of Moderna’s COVID-19 vaccine after reports of allergic reactions at one immunisation clinic. The clinic in question switched to another lot of Moderna vaccine after closing for a few hours.

Vaccines 136
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel

pharmaphorum

Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.

Vaccines 111
article thumbnail

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. The post Non-vaccine nasal spray could protect against COVID-19 appeared first on.

Vaccines 133
article thumbnail

mRNA vaccine trial shows efficiency in older adults with RSV

European Pharmaceutical Review

mRNA-1345 demonstrated vaccine efficacy (VE) of 83.7 percent in Moderna’s mRNA vaccine Phase III trial targeting respiratory syncytial virus (RSV) in older adults. ” Moderna’s mRNA vaccine – mRNA-1345. mRNA-1345 is an investigational RSV vaccine. Moderna launches two new mRNA vaccine programmes.

Vaccines 105
article thumbnail

Health Canada approves Novavax’s Covid-19 vaccine for adolescents

Pharmaceutical Technology

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccines 105
article thumbnail

EC approves Novavax’s Covid-19 vaccine CMA expansion for adolescents

Pharmaceutical Technology

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.

Vaccines 105